The subsidiary will enable pharmaceutical and other life science companies to leverage the wealth of data contained within the Medical Center’s genomics and health information technology resources, to accelerate drug discovery and development
Dr Leeland Ekstrom, Chief Operating Officer and founder, Nashville Biosciences. Photo credit: Business Wire
Vanderbilt University Medical Center (VUMC) announced the creation of a wholly owned subsidiary, Nashville Biosciences, to harness the power of its extensive genomic and bioinformatics resources to advance drug and diagnostics discovery and development.
Through Nashville Biosciences, pharmaceutical and other life science companies can leverage the wealth of data contained within the Medical Center’s genomics and health information technology resources to accelerate their discovery and development of new treatments for patients, while helping to support institutional research efforts.
“Partnering with the pharmaceutical and broader life sciences industry through Nashville Biosciences will enable VUMC to expand and support its mission of advancing translational and precision medicine,” said Dr Leeland Ekstrom, Chief Operating Officer of Nashville Biosciences.
Nashville Biosciences will serve as a commercial interface between outside companies and the formidable research resources housed in VUMC, including its comprehensive databank BioVU, which contains more than 250,000 DNA samples collected in the last decade, coupled with 2.8 million de-identified patient records.
“The creation of Nashville Biosciences will dramatically accelerate our ability to work with pharmaceutical and other partners to advance human health by accelerating rational drug and diagnostics development and use,“ said Dr Dan Roden, VUMC’s Senior VP for personalised medicine.
Among the capabilities that will distinguish the company are analytical methods developed for 'mining' DNA datasets. For example, researchers led by Dr Josh Denny, MS, VP of personalised medicine, have pioneered techniques such as PheWASTM that can link specific genetic mutations to their key clinical characteristics (known as disease phenotypes).
“Among academic medical centers, VUMC is widely recognized as a leader in the application of genomics and bioinformatics to drug development, an effort that is transforming the pharmaceutical industry,“ said Dr Leeland Ekstrom, Chief Operating Officer and founder, Nashville Biosciences.
Prior to the official launch of Nashville Biosciences, VUMC has been working with a number of leading pharmaceutical and diagnostics companies to leverage these resources, including Celgene Corporation, Pfizer, Goldfinch Bio and Population Bio.
These projects, each of which aims to discover new treatments for patients in disease areas of interest for each partner, as well as multiple other ongoing efforts, will transition to the new company in the coming weeks.
“We have only just started to scratch the surface of what is possible with genomics and informatics resources that can be coalesced for research in a comprehensive academic medical center,” said Gordon Bernard, MD, Executive VP for Research for VUMC.
“Partnering with Nashville Biosciences will greatly expand the national and global reach of these resources,” said Bernard.